Abstract：Objective To compare the clinical effect of whole brain radiotherapy (WBRT) for brain metastases from lung adenocarcinoma between patients with and without epithelial growth factor receptor (EGFR) mutations.Methods A retrospective analysis was performed for 89 patients with brain metastases from lung adenocarcinoma who were treated in our hospital from August 2010 to May 2015. EGFR testing was performed in all patients. WBRT (6-MV external X-ray beam) was performed at 30 Gy in 10 fractions or 40 Gy in 20 fractions;for patients with ≤3 brain metastases, simultaneous integrated boost intensity-modulated radiotherapy was performed at 40-45 Gy in 10 fractions or 50-60 Gy in 20 fractions. The response rate, intracranial progression-free survival (IPFS), and overall survival (OS) were compared between patients with EGFR mutations and patients with wild-type EGFR. The Kaplan-Meier method was used to calculate IPFS and OS, the log-rank test was used for survival difference analysis and univariate prognostic analysis, and the Cox model was used for multivariate prognostic analysis. Results For these 89 patients, the overall response rate was 62%, the median IPFS was 7.0 months (95%CI:6.060-7.940), and the median OS was 12.0 months (95%CI:9.539-14.465). The univariate and multivariate analyses showed that the response rate was associated with Karnofsky Performance Scale (KPS) score and EGFR mutation status (P=0.009 and 0.035);KPS score and EGFR mutation status were significant prognostic factors for IPFS (P=0.048 and 0.000);KPS score and primary tumor control were significant prognostic factors for OS (P=0.000 and 0.031). Conclusions After WBRT for brain metastases from lung adenocarcinoma, the patients with EGFR mutations have a higher response rate and a longer IPFS compared with those with wild-type EGFR, but there is no significant in OS between the two groups of patients.
Zhang Xiaqin,Li Hongwei,Wang Weili et al. Clinical effect of whole brain radiotherapy for brain metastases from lung adenocarcinoma in patients with or without EGFR mutations[J]. Chinese Journal of Radiation Oncology, 2017, 26(5): 527-531.
[1] Barnholtz-Sloan JS,Sloan AE,Davis FG,et al. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System[J].J Clin Oncol,2004,22(14):2865-2872.DOI:10.1200/JCO.2004.12.149. [2] Sekine I,Yamamoto N,Nishio K,et al. Emerging ethnic differences in lung cancer therapy[J].Br J Cancer,2008,99(11):1757-17 62.DOI:10.1038/sj.bjc.6604721. [3] Rodemann HP,Dittmann K,Toulany M.Radiation-induced EGFR-signaling and control of DNA-damage repair[J].Int J Radiat Biol,2007,83(11-12):781-791.DOI:10.1080/0955300070176997 0. [4] Lo HW.Nuclear mode of the EGFR signaling network:biology,prognostic value,and therapeutic implications[J].Discov Med,2010,10(50):44-51. [5] Dittmann K,Mayer C,Kehlbach R,et al. The radioprotector Bowman-Birk proteinase inhibitor stimulates DNA repair via epidermal growth factor receptor phosphorylation and nuclear transport[J].Radiother Oncol,2008,86(3):375-382.DOI:10.1016/j.radonc.2008.01.007. [6] Das AK,Sato M,Story MD,et al. Non-small-cell lung cancers with kinase domain mutations in the epidermal growth factor receptor are sensitive to ionizing radiation[J].Cancer Res,2006,66(19):9601-9608.DOI:10.1158/0008-5472.CAN-06-2627. [7] Das AK,Chen BP,Story MD,et al. Somatic mutations in the tyrosine kinase domain of epidermal growth factor receptor (EGFR) abrogate EGFR-mediated radioprotection in non-small cell lung carcinoma[J].Cancer Res,2007,67(11):5267-5274.DOI:10.1158/0008-5472.CAN-07-0242. [8] Eichler AF,Kahle KT,Wang DL,et al. EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer[J].Neuro Oncol,2010,12(11):1193-1199.DOI:10.1093/neuonc/noq076. [9] Lee HL,Chung TS,Ting LL,et al. EGFR mutations are associated with favorable intracranial response and progression-free survival following brain irradiation in non-small cell lung cancer patients with brain metastases[J].Radiat Oncol,2012,7(1):181.DOI:10.1186/1748-717X-7-181. [10] Hsiao SH,Lin HC,Chou YT,et al. Impact of epidermal growth factor receptor mutations on intracranial treatment response and survival after brain metastases in lung adenocarcinoma patients[J].Lung Cancer,2013,81(3):455-461.DOI:10.1016/ j.lungcan.2013.06.004. [11] Gow CH,Chien CR,Chang YL,et al. Radiotherapy in lung adenocarcinoma with brain metastases:effects of activating epidermal growth factor receptor mutations on clinical response[J].Clin Cancer Res,2008,14(1):162-168.DOI:10.1158/1078-0432.CCR-07-1468. [12] Gaspar L,Scott C,Rotman M,et al. Recursive partitioning analysis(RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials[J].Int J Radiat Oncol Biol Phys,1997,37(4):745-751.DOI:10.1016/S 0360-3016(96)00619-0. [13] Sperduto PW,Berkey B,Gaspar LE,et al. A new prognostic index and comparison to three other indices for patients with brain metastases:an analysis of 1,960 patients in the RTOG database[J].Int J Radiat Oncol Biol Phys,2008,70(2):510-514.DOI:10.1200/JCO.2011.38.0527. [14] Sun CX,Li T,Zheng X,et al. Recursive partitioning analysis classification and graded prognostic assessment for non-small cell lung cancer patients with brain metastasis:a retrospective cohort study[J].Chin J Cancer Res,2011,23(3):177-182.DOI:10.1007/s11670-011-0177-1. [15] Mok TS,Wu YL,Thongprasert S,et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma[J].N Engl J Med,2009,361(10):947-957.DOI:10.1056/NEJM oa 08 10699. [16] Zhou C,Wu YL,Chen GY,et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL,CTONG-0802):a multicentre,open-label,randomis-ed,phase 3 study[J].Lancet Oncol,2011,12(8):735-742.DOI:10.1016/S1470-2045(11)70184-X. [17] Rosell R,Carcereny E,Gervais R,et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC):a multicentre,open–label,randomised phase 3 trial[J].Lancet Oncol,2012,13(3):239-246.DOI:10.1016/S1470-2045(11)70393-X. [18] Khalifa J,Amini A,Popat S,et al. IASLC Advanced Radiation Technology Committee. Brain metastases from non-small cell lung cancer:radiation therapy in the era of targeted therapies[J].J Thorac Oncol,2016 Jun 22,DOI:10.1016/j.jth o.2016.06.002. [19] Linda JS,Lagerwaard FJ,Smit EF,et al. Phase Ⅰ study of concurrent whole brain radiotherapy and erlotinib for multiple brain metastases from non-small-cell lung cancer[J].Int J Radiat Oncol Biol Phys,2009,74(5):1391-13 96.DOI:10.1016/j.ijr069.2008.10.026. [20] Welsh JW,Komaki R,Amini A,et al. Phase Ⅱ trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer[J].J Clin Oncol,2013,31(7):895-902.DOI:10.1200/JCO.2011.40.11 74. [21] Lee SM,Lewanski CR,Counsell N,et al. Randomized trial of erlotinib plus whole-brain radiotherapy for NSCLC patients with multiple brain metastases[J].J Natl Cancer Inst,2014,106(7).pii:dju151.DOI:10.1093/jnci/dju151. [22] Magnuson WJ,Yeung JT,Guillod PD,et al.Impact of deferring radiation therapy in patients with epidermal growth factor receptor-mutant non-small cell lung cancer who develop brain metastases[J].Int J Radiat Oncol Biol Phys,2016,95(2):673-679.DOI:10.1016/j.ijrobp.2016.01.037. [23] Gerber NK,Yamada Y,Rimner A,et al. Erlotinib versus radiation therapy for brain metastasesin patients with EGFR-mutant lung adenocarcinoma[J].Int J Radiat Oncol BiolPhys,2014,89(2):322-329.DOI:10.1016/j.ijrobp.2014.02.022.
2017, Vol. 26 
